Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T19:42:27.353Z.
Calculation as of: 2026-10-06T19:42:27.353Z.
Quote observation: 2026-10-06T19:40:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69a1d57d3f318828ebe19021960b74268097702d5d6050a421f3255bba496414
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
MoonLake Immunotherapeutics
Market Cap
$923.17M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$926.80M
EV/Sales Ratio
11.41x
TTM Avg
10.07x
3Y Avg
9.06x
5Y Avg
9.06x
Market Cap
$911.72M
EV/Sales Ratio
2.74x
TTM Avg
2.28x
3Y Avg
2.71x
5Y Avg
2.71x
Market Cap
$943.21M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$953.01M
EV/Sales Ratio
87.65x
TTM Avg
120.79x
3Y Avg
120.79x
5Y Avg
120.79x
Market Cap
$889.91M
EV/Sales Ratio
4.81x
TTM Avg
36.22x
3Y Avg
50.65x
5Y Avg
36.89x
Market Cap
$959.06M
EV/Sales Ratio
N/A
TTM Avg
60100.68x
3Y Avg
43581.59x
5Y Avg
27036.85x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | $923.17M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $921.77M | 8.93x | 7.82x | 8.63x | 8.63x |
| Kura Oncology, Inc. (KURA)vs › | $926.80M | 11.41x | 10.07x | 9.06x | 9.06x |
| HealthStream, Inc. (HSTM)vs › | $911.72M | 2.74x | 2.28x | 2.71x | 2.71x |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $943.21M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $953.01M | 87.65x | 120.79x | 120.79x | 120.79x |
| Arbutus Biopharma Corp (ABUS)vs › | $889.91M | 4.81x | 36.22x | 50.65x | 36.89x |
| Savara Inc. (SVRA)vs › | $959.06M | N/A | 60100.68x | 43581.59x | 27036.85x |
| Bioventus Inc. (BVS)vs › | $886.49M | 1.93x | 1.63x | 1.56x | 1.52x |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $881.69M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
